25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Arovella Therapeutics Ltd
Buy, Hold or Sell?

Let's analyze Arovella together

I guess you are interested in Arovella Therapeutics Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Arovella Therapeutics Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Arovella Therapeutics Ltd

I send you an email if I find something interesting about Arovella Therapeutics Ltd.

1. Quick Overview

1.1. Quick analysis of Arovella (30 sec.)










1.2. What can you expect buying and holding a share of Arovella? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$0.01
Expected worth in 1 year
A$0.04
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
A$0.03
Return On Investment
14.4%

For what price can you sell your share?

Current Price per Share
A$0.20
Expected price per share
A$0.175 - A$0.205
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Arovella (5 min.)




Live pricePrice per Share (EOD)
A$0.20
Intrinsic Value Per Share
A$-0.08 - A$-0.05
Total Value Per Share
A$-0.07 - A$-0.04

2.2. Growth of Arovella (5 min.)




Is Arovella growing?

Current yearPrevious yearGrowGrow %
How rich?$7m$2.3m$4.6m66.3%

How much money is Arovella making?

Current yearPrevious yearGrowGrow %
Making money-$5.4m-$6.3m$902k16.4%
Net Profit Margin-51,447.3%-2,508.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Arovella (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#651 / 931

Most Revenue
#731 / 931

Most Profit
#429 / 931

Most Efficient
#906 / 931
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Arovella?

Welcome investor! Arovella's management wants to use your money to grow the business. In return you get a share of Arovella.

First you should know what it really means to hold a share of Arovella. And how you can make/lose money.

Speculation

The Price per Share of Arovella is A$0.195. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Arovella.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Arovella, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.01. Based on the TTM, the Book Value Change Per Share is A$0.01 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Arovella.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.01-2.7%-0.01-2.7%-0.01-3.1%-0.01-2.6%0.00-1.9%
Usd Book Value Change Per Share0.002.3%0.002.3%0.00-1.2%0.00-0.2%0.00-0.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.002.3%0.002.3%0.00-1.2%0.00-0.2%0.00-0.1%
Usd Price Per Share0.09-0.09-0.03-0.04-0.02-
Price to Earnings Ratio-16.98--16.98--5.21--8.19--7.71-
Price-to-Total Gains Ratio19.94-19.94--13.82--0.65-7.99-
Price to Book Ratio13.23-13.23-14.03-9.34-5.15-
Price-to-Total Gains Ratio19.94-19.94--13.82--0.65-7.99-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.1225575
Number of shares8159
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (8159 shares)36.01-2.66
Gains per Year (8159 shares)144.03-10.63
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101441340-11-21
202882780-21-32
304324220-32-43
405765660-43-54
507207100-53-65
608648540-64-76
7010089980-74-87
80115211420-85-98
90129612860-96-109
100144014300-106-120

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.022.01.00.0%
Book Value Change Per Share1.00.00.0100.0%1.02.00.033.3%2.03.00.040.0%5.05.00.050.0%12.011.00.052.2%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%5.00.018.021.7%
Total Gains per Share1.00.00.0100.0%1.02.00.033.3%2.03.00.040.0%5.05.00.050.0%12.011.00.052.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Arovella Therapeutics Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0070.0070%-0.004+152%-0.001+107%0.000+106%
Book Value Per Share--0.0110.0110%0.004+197%0.007+57%0.011-1%
Current Ratio--6.4466.4460%3.103+108%3.851+67%3.154+104%
Debt To Asset Ratio--0.1550.1550%0.309-50%0.236-34%0.209-26%
Debt To Equity Ratio--0.1830.1830%0.447-59%0.330-45%0.283-35%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--159158571.000159158571.0000%56520470.000+182%69535175.200+129%42591470.800+274%
Eps---0.008-0.0080%-0.010+16%-0.008-3%-0.006-28%
Ev To Ebitda Ratio---18.018-18.0180%-5.449-70%-10.261-43%-7.875-56%
Ev To Sales Ratio--9362.2699362.2690%139.248+6623%1984.843+372%994.320+842%
Free Cash Flow Per Share---0.007-0.0070%-0.006-9%-0.005-22%-0.004-36%
Free Cash Flow To Equity Per Share--0.0070.0070%-0.001+113%0.002+354%0.001+901%
Gross Profit Margin--1.1461.1460%1.043+10%1.038+10%1.019+12%
Intrinsic Value_10Y_max---0.046--------
Intrinsic Value_10Y_min---0.082--------
Intrinsic Value_1Y_max---0.004--------
Intrinsic Value_1Y_min---0.007--------
Intrinsic Value_3Y_max---0.013--------
Intrinsic Value_3Y_min---0.022--------
Intrinsic Value_5Y_max---0.023--------
Intrinsic Value_5Y_min---0.038--------
Market Cap206840400.000+28%148500800.000148500800.0000%53036000.000+180%65128208.000+128%40604361.600+266%
Net Profit Margin---514.473-514.4730%-25.084-95%-121.396-76%-62.735-88%
Operating Margin---522.126-522.1260%-27.616-95%-121.526-77%-63.162-88%
Operating Ratio--636.957636.9570%24.850+2463%143.527+344%74.037+760%
Pb Ratio18.422+28%13.22613.2260%14.030-6%9.336+42%5.146+157%
Pe Ratio-23.650-39%-16.979-16.9790%-5.209-69%-8.189-52%-7.706-55%
Price Per Share0.195+28%0.1400.1400%0.050+180%0.061+128%0.038+266%
Price To Free Cash Flow Ratio-29.367-39%-21.084-21.0840%-8.286-61%-11.966-43%-8.494-60%
Price To Total Gains Ratio27.771+28%19.93819.9380%-13.823+169%-0.655+103%7.985+150%
Quick Ratio--6.2306.2300%3.084+102%3.646+71%2.823+121%
Return On Assets---0.658-0.6580%-1.861+183%-1.082+64%-0.654-1%
Return On Equity---0.779-0.7790%-2.693+246%-1.514+94%-0.901+16%
Total Gains Per Share--0.0070.0070%-0.004+152%-0.001+107%0.000+106%
Usd Book Value--7056827.5407056827.5400%2375787.194+197%4492797.431+57%7161354.066-1%
Usd Book Value Change Per Share--0.0040.0040%-0.002+152%0.000+107%0.000+106%
Usd Book Value Per Share--0.0070.0070%0.002+197%0.004+57%0.007-1%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--100031161.874100031161.8740%35523115.395+182%43702857.613+129%26768739.398+274%
Usd Eps---0.005-0.0050%-0.006+16%-0.005-3%-0.004-28%
Usd Free Cash Flow---4426659.371-4426659.3710%-4022630.031-9%-3470457.711-22%-2829644.893-36%
Usd Free Cash Flow Per Share---0.004-0.0040%-0.004-9%-0.003-22%-0.003-36%
Usd Free Cash Flow To Equity Per Share--0.0040.0040%-0.001+113%0.001+354%0.000+901%
Usd Market Cap129999191.400+28%93332752.80093332752.8000%33333126.000+180%40933078.728+128%25519841.266+266%
Usd Price Per Share0.123+28%0.0880.0880%0.031+180%0.039+128%0.024+266%
Usd Profit---5496882.998-5496882.9980%-6398979.104+16%-5347196.044-3%-3936298.140-28%
Usd Revenue--10684.50010684.5000%255106.893-96%189649.247-94%1369230.868-99%
Usd Total Gains Per Share--0.0040.0040%-0.002+152%0.000+107%0.000+106%
 EOD+6 -2MRQTTM+0 -0YOY+29 -95Y+25 -1310Y+21 -17

3.3 Fundamental Score

Let's check the fundamental score of Arovella Therapeutics Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-23.650
Price to Book Ratio (EOD)Between0-118.422
Net Profit Margin (MRQ)Greater than0-514.473
Operating Margin (MRQ)Greater than0-522.126
Quick Ratio (MRQ)Greater than16.230
Current Ratio (MRQ)Greater than16.446
Debt to Asset Ratio (MRQ)Less than10.155
Debt to Equity Ratio (MRQ)Less than10.183
Return on Equity (MRQ)Greater than0.15-0.779
Return on Assets (MRQ)Greater than0.05-0.658
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Arovella Therapeutics Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.377
Ma 20Greater thanMa 500.188
Ma 50Greater thanMa 1000.182
Ma 100Greater thanMa 2000.179
OpenGreater thanClose0.190
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Arovella Therapeutics Ltd

Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally. The company product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.

Fundamental data was last updated by Penke on 2025-01-25 02:43:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Arovella earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Arovella to the Biotechnology industry mean.
  • A Net Profit Margin of -51,447.3% means that $-514.47 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Arovella Therapeutics Ltd:

  • The MRQ is -51,447.3%. The company is making a huge loss. -2
  • The TTM is -51,447.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-51,447.3%TTM-51,447.3%0.0%
TTM-51,447.3%YOY-2,508.4%-48,938.9%
TTM-51,447.3%5Y-12,139.6%-39,307.7%
5Y-12,139.6%10Y-6,273.5%-5,866.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-51,447.3%-101.2%-51,346.1%
TTM-51,447.3%-211.2%-51,236.1%
YOY-2,508.4%-208.6%-2,299.8%
5Y-12,139.6%-342.2%-11,797.4%
10Y-6,273.5%-487.5%-5,786.0%
4.3.1.2. Return on Assets

Shows how efficient Arovella is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Arovella to the Biotechnology industry mean.
  • -65.8% Return on Assets means that Arovella generated $-0.66 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Arovella Therapeutics Ltd:

  • The MRQ is -65.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -65.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-65.8%TTM-65.8%0.0%
TTM-65.8%YOY-186.1%+120.3%
TTM-65.8%5Y-108.2%+42.4%
5Y-108.2%10Y-65.4%-42.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-65.8%-12.4%-53.4%
TTM-65.8%-12.4%-53.4%
YOY-186.1%-11.9%-174.2%
5Y-108.2%-13.2%-95.0%
10Y-65.4%-15.3%-50.1%
4.3.1.3. Return on Equity

Shows how efficient Arovella is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Arovella to the Biotechnology industry mean.
  • -77.9% Return on Equity means Arovella generated $-0.78 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Arovella Therapeutics Ltd:

  • The MRQ is -77.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -77.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-77.9%TTM-77.9%0.0%
TTM-77.9%YOY-269.3%+191.4%
TTM-77.9%5Y-151.4%+73.5%
5Y-151.4%10Y-90.1%-61.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-77.9%-15.9%-62.0%
TTM-77.9%-17.1%-60.8%
YOY-269.3%-15.4%-253.9%
5Y-151.4%-19.5%-131.9%
10Y-90.1%-20.6%-69.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Arovella Therapeutics Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Arovella is operating .

  • Measures how much profit Arovella makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Arovella to the Biotechnology industry mean.
  • An Operating Margin of -52,212.6% means the company generated $-522.13  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Arovella Therapeutics Ltd:

  • The MRQ is -52,212.6%. The company is operating very inefficient. -2
  • The TTM is -52,212.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-52,212.6%TTM-52,212.6%0.0%
TTM-52,212.6%YOY-2,761.6%-49,450.9%
TTM-52,212.6%5Y-12,152.6%-40,059.9%
5Y-12,152.6%10Y-6,316.2%-5,836.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-52,212.6%-201.5%-52,011.1%
TTM-52,212.6%-316.3%-51,896.3%
YOY-2,761.6%-217.2%-2,544.4%
5Y-12,152.6%-368.2%-11,784.4%
10Y-6,316.2%-486.9%-5,829.3%
4.3.2.2. Operating Ratio

Measures how efficient Arovella is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 636.96 means that the operating costs are $636.96 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Arovella Therapeutics Ltd:

  • The MRQ is 636.957. The company is inefficient in keeping operating costs low. -1
  • The TTM is 636.957. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ636.957TTM636.9570.000
TTM636.957YOY24.850+612.106
TTM636.9575Y143.527+493.429
5Y143.52710Y74.037+69.490
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ636.9572.160+634.797
TTM636.9573.220+633.737
YOY24.8503.231+21.619
5Y143.5274.740+138.787
10Y74.0376.437+67.600
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Arovella Therapeutics Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Arovella is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.45 means the company has $6.45 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Arovella Therapeutics Ltd:

  • The MRQ is 6.446. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.446. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.446TTM6.4460.000
TTM6.446YOY3.103+3.342
TTM6.4465Y3.851+2.595
5Y3.85110Y3.154+0.696
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.4463.608+2.838
TTM6.4463.862+2.584
YOY3.1034.596-1.493
5Y3.8515.968-2.117
10Y3.1546.183-3.029
4.4.3.2. Quick Ratio

Measures if Arovella is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Arovella to the Biotechnology industry mean.
  • A Quick Ratio of 6.23 means the company can pay off $6.23 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Arovella Therapeutics Ltd:

  • The MRQ is 6.230. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.230. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.230TTM6.2300.000
TTM6.230YOY3.084+3.147
TTM6.2305Y3.646+2.584
5Y3.64610Y2.823+0.823
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.2303.010+3.220
TTM6.2303.351+2.879
YOY3.0844.345-1.261
5Y3.6465.954-2.308
10Y2.8236.490-3.667
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Arovella Therapeutics Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Arovella assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Arovella to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.15 means that Arovella assets are financed with 15.5% credit (debt) and the remaining percentage (100% - 15.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Arovella Therapeutics Ltd:

  • The MRQ is 0.155. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.155. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.155TTM0.1550.000
TTM0.155YOY0.309-0.154
TTM0.1555Y0.236-0.081
5Y0.23610Y0.209+0.027
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1550.340-0.185
TTM0.1550.342-0.187
YOY0.3090.316-0.007
5Y0.2360.364-0.128
10Y0.2090.384-0.175
4.5.4.2. Debt to Equity Ratio

Measures if Arovella is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Arovella to the Biotechnology industry mean.
  • A Debt to Equity ratio of 18.3% means that company has $0.18 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Arovella Therapeutics Ltd:

  • The MRQ is 0.183. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.183. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.183TTM0.1830.000
TTM0.183YOY0.447-0.264
TTM0.1835Y0.330-0.147
5Y0.33010Y0.283+0.047
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1830.385-0.202
TTM0.1830.427-0.244
YOY0.4470.391+0.056
5Y0.3300.450-0.120
10Y0.2830.492-0.209
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Arovella generates.

  • Above 15 is considered overpriced but always compare Arovella to the Biotechnology industry mean.
  • A PE ratio of -16.98 means the investor is paying $-16.98 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Arovella Therapeutics Ltd:

  • The EOD is -23.650. Based on the earnings, the company is expensive. -2
  • The MRQ is -16.979. Based on the earnings, the company is expensive. -2
  • The TTM is -16.979. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-23.650MRQ-16.979-6.670
MRQ-16.979TTM-16.9790.000
TTM-16.979YOY-5.209-11.770
TTM-16.9795Y-8.189-8.790
5Y-8.18910Y-7.706-0.483
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-23.650-2.247-21.403
MRQ-16.979-2.704-14.275
TTM-16.979-3.242-13.737
YOY-5.209-3.350-1.859
5Y-8.189-6.130-2.059
10Y-7.706-6.719-0.987
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Arovella Therapeutics Ltd:

  • The EOD is -29.367. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -21.084. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -21.084. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-29.367MRQ-21.084-8.283
MRQ-21.084TTM-21.0840.000
TTM-21.084YOY-8.286-12.798
TTM-21.0845Y-11.966-9.118
5Y-11.96610Y-8.494-3.472
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-29.367-3.054-26.313
MRQ-21.084-3.598-17.486
TTM-21.084-3.833-17.251
YOY-8.286-4.518-3.768
5Y-11.966-8.223-3.743
10Y-8.494-9.265+0.771
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Arovella is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 13.23 means the investor is paying $13.23 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Arovella Therapeutics Ltd:

  • The EOD is 18.422. Based on the equity, the company is expensive. -2
  • The MRQ is 13.226. Based on the equity, the company is expensive. -2
  • The TTM is 13.226. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD18.422MRQ13.226+5.196
MRQ13.226TTM13.2260.000
TTM13.226YOY14.030-0.804
TTM13.2265Y9.336+3.890
5Y9.33610Y5.146+4.190
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD18.4221.924+16.498
MRQ13.2262.237+10.989
TTM13.2262.443+10.783
YOY14.0302.459+11.571
5Y9.3363.744+5.592
10Y5.1464.444+0.702
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-06-302021-06-302022-06-302023-06-302024-06-30
Total Other Income Expense Net -2,9321,637-1,295270-1,024-525-1,5493,6152,065



6.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets13,285
Total Liabilities2,057
Total Stockholder Equity11,228
 As reported
Total Liabilities 2,057
Total Stockholder Equity+ 11,228
Total Assets = 13,285

Assets

Total Assets13,285
Total Current Assets13,154
Long-term Assets131
Total Current Assets
Cash And Cash Equivalents 12,714
Other Current Assets 439
Total Current Assets  (as reported)13,154
Total Current Assets  (calculated)13,154
+/-0
Long-term Assets
Property Plant Equipment 131
Other Assets 0
Long-term Assets  (as reported)131
Long-term Assets  (calculated)131
+/- 0

Liabilities & Shareholders' Equity

Total Current Liabilities2,041
Long-term Liabilities16
Total Stockholder Equity11,228
Total Current Liabilities
Short-term Debt 785
Accounts payable 984
Other Current Liabilities 1,057
Total Current Liabilities  (as reported)2,041
Total Current Liabilities  (calculated)2,825
+/- 785
Long-term Liabilities
Long-term Liabilities  (as reported)16
Long-term Liabilities  (calculated)0
+/- 16
Total Stockholder Equity
Common Stock104,296
Retained Earnings -95,506
Accumulated Other Comprehensive Income 2,438
Total Stockholder Equity (as reported)11,228
Total Stockholder Equity (calculated)11,228
+/-0
Other
Capital Stock104,296
Cash and Short Term Investments 12,714
Common Stock Shares Outstanding 941,423
Current Deferred Revenue136
Liabilities and Stockholders Equity 13,285
Net Debt -12,714
Net Invested Capital 11,228
Net Working Capital 11,113
Property Plant and Equipment Gross 338



6.3. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-30
> Total Assets 
6,117
3,144
4,653
16,096
14,951
16,629
20,998
16,064
16,611
11,902
13,526
9,755
10,729
20,347
22,821
19,515
20,016
16,642
16,253
6,707
10,687
9,212
5,471
13,285
13,2855,4719,21210,6876,70716,25316,64220,01619,51522,82120,34710,7299,75513,52611,90216,61116,06420,99816,62914,95116,0964,6533,1446,117
   > Total Current Assets 
4,342
1,152
1,220
7,357
5,556
6,212
7,869
6,234
8,009
2,793
5,779
3,054
2,432
7,485
9,344
5,293
4,610
1,071
5,595
2,035
7,343
6,588
5,219
13,154
13,1545,2196,5887,3432,0355,5951,0714,6105,2939,3447,4852,4323,0545,7792,7938,0096,2347,8696,2125,5567,3571,2201,1524,342
       Cash And Cash Equivalents 
4,326
643
726
3,767
1,827
975
835
489
2,899
834
3,561
1,590
753
3,990
6,252
2,449
1,770
98
4,314
977
6,717
6,071
5,175
12,714
12,7145,1756,0716,7179774,314981,7702,4496,2523,9907531,5903,5618342,8994898359751,8273,7677266434,326
       Short-term Investments 
0
0
0
0
0
1,220
1,885
117
119
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000001191171,8851,22000000
       Net Receivables 
1
504
223
1,124
1,356
1,012
1,516
2,285
1,456
396
456
671
635
750
1,319
773
1,608
791
1,121
216
534
36
10
0
010365342161,1217911,6087731,3197506356714563961,4562,2851,5161,0121,3561,1242235041
       Other Current Assets 
15
4
5
88
188
307
48
412
3,291
1,538
1,121
77
241
957
233
939
122
84
115
819
617
480
33
439
4393348061781911584122939233957241771,1211,5383,29141248307188885415
   > Long-term Assets 
1,775
1,993
3,433
8,739
9,395
10,417
13,130
9,830
8,602
9,110
7,747
6,700
8,297
12,862
13,476
14,222
15,405
15,571
10,658
4,673
3,344
2,625
252
131
1312522,6253,3444,67310,65815,57115,40514,22213,47612,8628,2976,7007,7479,1108,6029,83013,13010,4179,3958,7393,4331,9931,775
       Property Plant Equipment 
10
77
1,083
1,816
1,904
2,266
2,441
4,919
4,568
105
100
60
117
312
389
272
232
173
367
422
433
371
50
131
13150371433422367173232272389312117601001054,5684,9192,4412,2661,9041,8161,0837710
       Goodwill 
0
0
0
4,085
4,177
4,635
6,048
2,355
959
966
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000009669592,3556,0484,6354,1774,085000
       Intangible Assets 
1,765
1,765
2,066
2,476
2,503
2,503
2,493
2,493
2,193
8,988
7,646
6,640
8,180
12,549
13,088
13,951
15,173
15,399
10,291
4,251
2,911
2,253
0
0
002,2532,9114,25110,29115,39915,17313,95113,08812,5498,1806,6407,6468,9882,1932,4932,4932,5032,5032,4762,0661,7651,765
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,119
2,779
2,121
0
0
002,1212,7794,1190000000000000000000
> Total Liabilities 
4
146
885
2,821
3,227
3,278
6,671
5,554
7,769
3,557
2,494
2,743
4,039
4,355
3,520
2,909
3,163
5,178
2,276
2,572
1,706
1,595
1,691
2,057
2,0571,6911,5951,7062,5722,2765,1783,1632,9093,5204,3554,0392,7432,4943,5577,7695,5546,6713,2783,2272,8218851464
   > Total Current Liabilities 
4
101
617
2,287
2,763
1,804
5,103
5,334
5,933
2,283
2,494
2,743
3,439
2,480
3,520
2,909
1,361
3,835
1,349
2,022
1,695
1,509
1,682
2,041
2,0411,6821,5091,6952,0221,3493,8351,3612,9093,5202,4803,4392,7432,4942,2835,9335,3345,1031,8042,7632,2876171014
       Short-term Debt 
3
21
229
1,538
2,013
1,124
2,549
3,233
2,468
719
1,194
701
562
0
1,725
1,730
0
2,023
36
-93
-124
-274
0
785
7850-274-124-93362,02301,7301,72505627011,1947192,4683,2332,5491,1242,0131,538229213
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
36
12
6
1
0
0
00161236000000000000000000
       Accounts payable 
0
80
150
620
517
291
2,318
1,314
1,737
1,336
947
979
968
1,681
1,578
994
1,361
353
512
732
227
752
773
984
9847737522277325123531,3619941,5781,6819689799471,3361,7371,3142,318291517620150800
       Other Current Liabilities 
1
81
238
128
233
389
236
787
1,728
228
353
1,062
1,909
799
217
186
0
1,459
801
333
1,197
349
756
1,057
1,0577563491,1973338011,45901862177991,9091,0623532281,728787236389233128238811
   > Long-term Liabilities 
0
45
268
534
463
1,474
1,568
220
1,835
1,274
61
0
600
1,875
0
0
1,803
1,342
927
550
11
87
9
16
16987115509271,3421,803001,8756000611,2741,8352201,5681,474463534268450
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,803
26
17
4
3
77
0
0
00773417261,8030000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
545
8
9
9
0
09985450000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,119
2,779
2,121
0
0
002,1212,7794,1190000000000000000000
> Total Stockholder Equity
6,113
2,998
3,767
13,275
11,725
13,351
14,327
10,264
8,842
8,346
11,032
7,012
6,690
13,949
17,269
16,606
16,852
11,465
13,977
4,135
8,982
7,617
3,780
11,228
11,2283,7807,6178,9824,13513,97711,46516,85216,60617,26913,9496,6907,01211,0328,3468,84210,26414,32713,35111,72513,2753,7672,9986,113
   Common Stock
6,565
4,070
5,905
16,380
16,759
17,704
20,818
26,377
29,192
31,740
38,621
38,858
40,129
48,945
55,574
55,717
57,139
57,205
67,386
67,386
77,003
83,536
88,872
104,296
104,29688,87283,53677,00367,38667,38657,20557,13955,71755,57448,94540,12938,85838,62131,74029,19226,37720,81817,70416,75916,3805,9054,0706,565
   Retained Earnings -95,506-87,055-77,025-68,472-64,889-55,712-47,917-42,458-41,163-38,932-35,565-33,513-33,268-28,758-24,249-19,228-15,791-6,416-4,876-5,034-3,105-2,138-1,072-451
   Capital Surplus 000000000000000000000000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 
0
-1
0
0
0
0
-176
-434
-1,399
0
86
158
0
0
0
-56
0
0
0
1,630
451
1,105
1,964
0
01,9641,1054511,630000-56000158860-1,399-434-1760000-10



6.4. Balance Sheets

Currency in AUD. All numbers in thousands.




6.5. Cash Flows

Currency in AUD. All numbers in thousands.




6.6. Income Statements

Currency in AUD. All numbers in thousands.